Pink hypopyon had been reported in cases of Serratia marcescens endophthalmitis 1 and leukaemia uveitis. 2 We report for the first time the presentation of a pink hypopyon caused by Klebsiella ...

SEATTLE — Virginia Mason Franciscan Health confirmed two more deaths among infected patients after a Klebsiella pneumoniae bacterial outbreak began in late 2022. The Klebsiella pneumoniae bacteria ...

A Taiwanese study has demonstrated that human placental mesenchymal stem cells (PMSCs) were therapeutic in hypervirulent Klebsiella pneumonia (hvKp) intra-abdominal infections (IAIs) by secreting ...

Bacteria are fast evolving resistance to antibiotics, and one of the most worrying of these so-called “superbugs” is Klebsiella pneumoniae. Once largely confined to hospitals, more deadly and ...

The downtown Seattle location is experiencing an outbreak of Klebsiella pneumoniae, which according to the Centers for Disease Control and Prevention (CDC), can lead to infections such as urinary ...

A Seattle medical center is reporting 31 confirmed cases of a bacterial infection since October, according a news release from the Virginia Mason Medical Center. The most recent confirmed case was ...

Klebsiella pneumonia is a rare, life-threatening bacterial infection, which has become increasingly prevalent in many countries. New research suggests that there may be new promises for a bioconjugate ...

A bacterial outbreak at Virginia Mason Franciscan Health in Seattle, Washington, has infected a total of 31 patients, according to a press release on the hospital’s website. Four of the 31 patients ...

A mouse study at Washington University School of Medicine in St. Louis points to data that could be key to developing an effective vaccine for the bacterium Klebsiella pneumoniae. The bug is often ...

Four patients at a downtown Seattle hospital are dead in connection to an outbreak of a bacteria often found in health care settings that has developed resistance to some antibiotics. The infected ...

BOSTON & ST. LOUIS--(BUSINESS WIRE)--Omniose, a company developing polysaccharide conjugate vaccines against serious bacterial threats, has been awarded a $3.6 million grant for the development of a ...